UMN Pharma of Japan signs bio-manufacturing deal with DSM Biologics

Published: 10-Nov-2006

Japanese drug developer UMN Pharma has signed a biopharmaceutical agreement with DSM Biologics in the US based on the PER.C6 manufacturing platform


Japanese drug developer UMN Pharma has signed a biopharmaceutical agreement with DSM Biologics in the US based on the PER.C6 manufacturing platform

DSM Biologics will provide process and analytical development services and cGMP manufacturing batches for UMN Pharma's UMN-03 fusion protein developed for the treatment of muscular dystrophy and metabolic diseases such as obesity and type II diabetes mellitus.

The services will be provided out of DSM Biologics" FDA-approved manufacturing facility in Groningen. The deal follows the license agreement that was signed in March this year between UMN Pharma, DSM Biologics and Crucell.

Headquartered in Akita, UMN Pharma has a diverse pipeline of novel small molecule and protein drug candidates targeted to cancer, diabetes and other major therapeutic markets. Four products are in preclinical development with the first clinical study scheduled for early 2007.

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Read more
Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Ingredients

dsm-firmenich launches pharmaceutical taste solutions portfolio

The range aims to improve the taste and sensory experience of solid, liquid or semi-solid dosage forms
Ingredients

dsm-firmenich's CBtru demonstrates similar bioavailability to commercially available Epidiolex

The cannabidiol (CBD)-based drug product intermediate is absorbed into the bloodstream at a similar level compared with the only commercially approved CBD drug, Epidiolex
Ingredients

dsm-firmenich showcases excipient and sustainability solutions at CPHI Milan

The company will present its range of solutions designed to boost patient compliance, while also exhibiting its pharma-grade CBD ingredient
Ingredients

The roadmap to success in the cannabinoid drug development journey

The key to success in the development and registration of cannabinoid-based medicines hinges on choosing a GMP-certified high-purity active ingredient that is of natural origin and supported by regulatory documentation. Drug developers looking to take product development further still should also consider patient-centricity during formulation and strategies to boost the efficacy of cannabinoids by optimising their bioavailability profile
Manufacturing

dsm-firmenich initiates patent infringement action

dsm-firmenich asserts that Shengda’s production of a key biotin intermediate at its Anhui site is an unlawful use of patented technology
Ingredients

What role can CBD play to support mental health?

Talking to Dr Kevin Robinson (KSR), DSM’s Clinical Project Scientist, Mariana Coelho (MC), shares the latest scientific findings behind CBD and how it could help to support mental health and well-being on a global scale, especially as the demand for viable treatments continues to grow
Subscribe now